Anne M. Asemissen

Hamburg, HH 20251, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

A Combined Cyto- and Histopathological Diagnostic Approach Reduces Time to Diagnosis and Time to Therapy in First Manifestation of Metastatic Spinal Disease: A Cohort Study.

A Combined Cyto- and Histopathological Diagnostic Approach Reduces Time to Diagnosis and Time to Therapy in First Manifestation of Metastatic Spinal Disease: A Cohort Study.

Journal: Cancers
Published: March 18, 2024

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.

Journal: The Lancet. Haematology
Published: June 11, 2022

Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM.

Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM.

Journal: Blood advances
Published: May 04, 2022

Leishmania infantum reactivation with secondary IgA nephropathy.

Leishmania infantum reactivation with secondary IgA nephropathy.

Journal: Journal of travel medicine
Published: February 12, 2022

Surgical Site Cytology to Diagnose Spinal Lesions.

Surgical Site Cytology to Diagnose Spinal Lesions.

Journal: Diagnostics (Basel, Switzerland)
Published: November 30, 2021

Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial.

Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial.

Journal: Leukemia
Published: June 28, 2021

Pancytopenia of unknown origin in a 52-year-old patient

Pancytopenia of unknown origin in a 52-year-old patient

Journal: Der Internist
Published: April 11, 2019

Fulminant blast crisis with de novo 11q23 rearrangement in a Philadelphia-positive CML patient undergoing treatment with dasatinib.

Fulminant blast crisis with de novo 11q23 rearrangement in a Philadelphia-positive CML patient undergoing treatment with dasatinib.

Journal: Tumori
Published: April 03, 2019

Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide.

Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide.

Journal: Haematologica
Published: October 08, 2018

The beauty and the beast: lymphoma-like morphology of myeloid blast phase in CML.

The beauty and the beast: lymphoma-like morphology of myeloid blast phase in CML.

Journal: Blood
Published: September 09, 2017

T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker.

T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker.

Journal: International journal of cancer
Published: August 09, 2016

If it ain't broke, don't fix it!

If it ain't broke, don't fix it!

Journal: Haematologica
Published: November 08, 2011
Showing 1-12 of 12

Last Updated: 09/26/2026